STOCK TITAN

Ainos Inc Stock Price, News & Analysis

AIMD Nasdaq

Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.

Ainos Inc (NASDAQ: AIMD) delivers innovative healthcare solutions through its pioneering work in low-dose interferon therapeutics and AI-powered diagnostics. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, strategic partnerships, and technological breakthroughs.

Access timely reports on VELDONA clinical trial progress, AI Nose platform deployments, and regulatory milestones. Our curated collection features earnings announcements, research collaborations, and product innovation updates directly from corporate sources. All content undergoes strict verification to ensure accuracy and compliance with financial disclosure standards.

Key focus areas include autoimmune disease research advancements, veterinary medicine applications, and cross-industry implementations of olfactory sensing technology. Regular updates provide insights into how Ainos integrates biologics with artificial intelligence to address critical healthcare challenges.

Bookmark this page for verified updates on Ainos' progress in redefining patient care through science-driven solutions. Visit regularly to stay informed about emerging opportunities in biotech innovation and AI-driven healthcare.

Rhea-AI Summary

Ainos (NASDAQ:AIMD) announced its reclassification under GICS to Technology Hardware, Storage & Peripherals sector (Code 45202030), effective October 1, 2025. The company, transitioning from biotechnology, is positioning itself as a technology innovator in digital olfaction with its AI Nose platform powered by smell language model (SLM).

Key achievements include a 435% year-over-year revenue growth in 1H 2025 from senior care initiatives in Japan and securing a $2.1 million multi-year SmellTech-as-a-Service subscription contract for semiconductor manufacturing. Ainos has established strategic partnerships with five industry leaders: ASE Technology Holding, Topco Scientific, Kenmec Mechanical Engineering, Solomon Technology, and ugo, Inc., to accelerate SmellTech adoption across semiconductors, robotics, and automation sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) has expanded its intellectual property portfolio with seven new AI Nose patents across Europe, Germany, Taiwan, and China, bringing its total patent count to 123 active patents. The company's AI-powered scent digitization platform, AI Nose, is being developed for multiple industries including healthcare, semiconductors, smart factories, and robotics.

The technology enables machines to detect and analyze scents, with applications ranging from patient monitoring in healthcare to process optimization in semiconductor manufacturing. Under CEO Eddy Tsai's leadership, Ainos is advancing its SmellTech-as-a-Service business model and maintaining its trajectory toward 2026 commercialization goals.

[ "Expansion of patent portfolio to 123 patents across major markets", "Broad application potential across multiple high-value industries", "Strong IP protection creating competitive barriers", "Clear commercialization timeline with 2026 milestone" ]
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
AI
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) received recognition from Water Tower Research regarding its strategic partnership with Topco Scientific, marking the company's fifth industrial alliance in 2025. The partnership aims to accelerate the global commercialization of Ainos' AI Nose platform by 2026.

Topco, with $1.9 billion in annual revenue and 1,900 employees, will promote and distribute AI Nose across Taiwan, Japan, Southeast Asia, and the U.S. This follows Ainos' recent $2.1 million three-year SmellTech-as-a-Service subscription order from ASEH. The company has also showcased its technology at major industry events including Automation Taipei 2025 and SEMICON Taiwan 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
AI
Rhea-AI Summary

Ainos (NASDAQ:AIMD) has signed a strategic distribution agreement with Topco Scientific (TWSE: 5434) to accelerate the global commercialization of its AI Nose technology. Under the agreement, Topco will serve as Ainos' distributor in Taiwan, Japan, Southeast Asia, and the United States.

Topco will handle the distribution of AI Nose platform components, including modules, systems, consumables, and SmellTech-as-a-Service subscriptions, while providing installation, maintenance, and regulatory support. The partnership leverages Topco's 35-year industry presence and established relationships in semiconductors, optoelectronics, renewable energy, and healthcare sectors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.62%
Tags
AI
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) announced it will showcase its innovative AI Nose industrial module at SEMICON Taiwan 2025, taking place September 10-12 at the Taipei Nangang Exhibition Center. The AI Nose represents the first commercial AI olfaction system that converts scent into machine-readable data, featuring a globally patented architecture combining multi-sensor integration with cloud-based AI.

The company is introducing a SmellTech-as-a-Service (SaaS) subscription model, offering software upgrades, cloud-based AI enhancements, and data analytics. The technology targets multiple sectors including semiconductor fabrication, smart manufacturing, hospital infection control, and environmental monitoring. The event is expected to attract over 1,200 semiconductor companies and more than 100,000 industry professionals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
AI
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) is transforming from a biotech company into a pioneering SmellTech leader through its AI Nose platform. The Water Tower Research report highlights the company's strategic pivot following its 2021 acquisition of AI Nose, which enables artificial intelligence to detect and process scents.

The company has secured strategic partnerships with major industry players including ASE Technology Holding, ugo, Inc., Kenmec Mechanical Engineering, and Solomon Technology. A significant milestone includes a $2.1 million contract for 1,400 AI Nose units in the semiconductor sector, with potential expansion to 15,000 units.

Ainos plans to scale its AI Nose deployment in 2026, implementing a SmellTech-as-a-Service (SaaS) model across healthcare, robotics, semiconductors, and smart manufacturing sectors. The company's competitive advantage stems from its proprietary smell language model (SLM) and extensive Smell ID data collection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.03%
Tags
AI
Rhea-AI Summary

Ainos (NASDAQ:AIMD) has received coverage initiation from Water Tower Research under its Technology research platform, marking its transition from the Emerging Growth category. The company's AI Nose platform, powered by a proprietary Smell Language Model (SLM), is transforming digital olfaction technology across multiple sectors.

Key achievements include first AI Nose revenues of $110K in 1H25 from Japan's senior care pilot program and a significant $2.1M SmellTech-as-a-Service order. The company is expanding beyond healthcare into robotics and industrial applications through strategic partnerships with ASEH, Kenmec, Solomon Technology, and ugo, targeting the $70+ billion e-nose market. Additionally, Ainos continues advancing its VELDONA® therapeutic programs for various medical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
AI
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) has launched the world's first commercial AI Nose module, a groundbreaking AI-powered scent detection system designed for industrial and healthcare applications. The device combines multi-sensor arrays with a proprietary smell language model (SLM) to enable machine-based scent analysis with human-like accuracy.

The company is introducing a SmellTech-as-a-Service (SaaS) subscription model, providing software upgrades, cloud-based AI enhancements, and data analytics. Initial deployments are targeted at semiconductor fabrication, smart manufacturing, hospital infection control, and environmental monitoring sectors. The technology will debut at Automation Taipei 2025 in partnership with Kenmec and ugo.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.69%
Tags
AI
-
Rhea-AI Summary

Ainos (NASDAQ:AIMD) reported Q2 2025 financial results highlighting significant commercial progress for its AI Nose scent digitization platform. The company secured its first three-year subscription order worth $2.1 million for semiconductor manufacturing applications and generated initial revenue from the senior care sector.

AI Nose demonstrated strong performance metrics, achieving 85% accuracy in eldercare hygiene detection, 80% in semiconductor facilities, and 90% in food/beverage scent classification. The company unveiled a 90-day roadmap targeting approximately 1,400 pilot deployments, with plans to expand to 5,000 units in Phase 1 and potentially 15,000 units in Phase 2.

Ainos established strategic partnerships with key players including ASE Technology, Solomon, and Kenmec to accelerate AI Nose adoption across robotics, semiconductors, and smart manufacturing. The company also completed a 1-for-5 reverse stock split to regain Nasdaq compliance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.69%
Tags
Rhea-AI Summary

Ainos (NASDAQ:AIMD), a company specializing in AI-powered scent detection, has announced its participation in an upcoming fireside chat with Water Tower Research on August 20, 2025, at 11:00 a.m. ET.

During the chat, the company will discuss its AI Nose technology, recent strategic partnerships, and deployment progress. Management will also address market opportunities, upcoming milestones for 2025-2026, and position Ainos as a core technology company. The event will be available for replay on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences

FAQ

What is the current stock price of Ainos (AIMD)?

The current stock price of Ainos (AIMD) is $3.59 as of October 2, 2025.

What is the market cap of Ainos (AIMD)?

The market cap of Ainos (AIMD) is approximately 16.4M.
Ainos Inc

Nasdaq:AIMD

AIMD Rankings

AIMD Stock Data

16.42M
1.88M
56.73%
0.13%
2.59%
Medical Devices
Pharmaceutical Preparations
Link
United States
SAN DIEGO